Final Self-Assessment: The 2016 Advanced Clinical Educator Program in Multiple Myeloma
Hematology-Oncology
Curriculum:
The 2016 Advanced Clinical Educator Program in Multiple Myeloma: A CE-Certified Serial Learning Approach to Bridging Communication and Educational Gaps in MM
The 2016 Advanced Clinical Educator Program in Multiple Myeloma: A CE-Certified Serial Learning Approach to Bridging Communication and Educational Gaps in MM
Launch Date:
March 24, 2017
March 24, 2017
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
oncology/hematology nurses
Relevant Terms:
multiple myeloma
Beth Faiman, PhD, RN, APRN-BC, AOCN®
Beth Faiman, PhD, RN, APRN-BC, AOCN®
Adult Nurse Practitioner
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio
Adjunct Faculty
Ursuline College
Case Western Reserve University
Kent State University
Cleveland, Ohio
Bio
Dr. Beth Faiman is an Adult Nurse Practitioner in the Department of Hematologic Oncology and Blood Disorders at the Cleveland Clinic Taussig Cancer Institute in Ohio. She is an Adjunct Faculty member at Ursuline College, Case Western Reserve University, and Kent State University, as well as an appointed delegate on the International Myeloma Foundation Nurse Leadership Board.
Dr. Faiman is an active author, presenter, and educator on the topics of multiple myeloma, plasma cell dyscrasias, general cancer diagnosis and treatment, as well as management of skeletal and other cancer complications. Dr. Faiman is currently editor-in-chief of The Oncology Nurse - APN/PA. She has edited books and written several book chapters related to diagnosis and management of multiple myeloma and blood disorders and numerous articles related to the diagnosis and treatment of myeloma, palliation, and cancer symptom management.
Dr. Faiman earned an MSN and certification as an adult nurse practitioner from Kent State University, Ohio, and a PhD in clinical research and nursing science from Case Western Reserve University in Cleveland, Ohio. She is an advanced oncology certified nurse.
Dr. Faiman is an active author, presenter, and educator on the topics of multiple myeloma, plasma cell dyscrasias, general cancer diagnosis and treatment, as well as management of skeletal and other cancer complications. Dr. Faiman is currently editor-in-chief of The Oncology Nurse - APN/PA. She has edited books and written several book chapters related to diagnosis and management of multiple myeloma and blood disorders and numerous articles related to the diagnosis and treatment of myeloma, palliation, and cancer symptom management.
Dr. Faiman earned an MSN and certification as an adult nurse practitioner from Kent State University, Ohio, and a PhD in clinical research and nursing science from Case Western Reserve University in Cleveland, Ohio. She is an advanced oncology certified nurse.
Sandra E. Kurtin, MS, RN, ANP-C, AOCN®
Sandra E. Kurtin, MS, RN, ANP-C, AOCN®
Nurse Practitioner
Clinical Assistant Professor of Medicine
Adjunct Clinical Assistant Professor of Nursing
The University of Arizona Cancer Center
Tucson, AZ
Bio
Sandra E. Kurtin is a Nurse Practitioner, Clinical Assistant Professor of Medicine, and Adjunct Clinical Assistant Professor of Nursing at The University of Arizona Cancer Center in Tucson. Ms. Kurtin maintains a busy clinical practice in a National Cancer Institute–designated comprehensive cancer center with expertise in hematological malignancies, gastrointestinal malignancies, clinical trials, symptom management, cancer caregivers, and health informatics.
Ms. Kurtin is widely published in peer-reviewed journals, lectures nationally and internationally, and maintains active membership in local, regional, national, and international professional and patient advocacy oncology organizations.
Ms. Kurtin earned an MSN from The University of Arizona in Tucson and is an advanced oncology certified nurse. She is currently enrolled in the PhD program with a focus on nursing and health informatics.
Ms. Kurtin is widely published in peer-reviewed journals, lectures nationally and internationally, and maintains active membership in local, regional, national, and international professional and patient advocacy oncology organizations.
Ms. Kurtin earned an MSN from The University of Arizona in Tucson and is an advanced oncology certified nurse. She is currently enrolled in the PhD program with a focus on nursing and health informatics.
| 1. | Explain the pathophysiology of multiple myeloma | 2. | Assess the diagnostic workup of patients with multiple myeloma |
| 3. | Describe the various methods of staging multiple myeloma | 4. | Assess the latest data on the safety and efficacy of current and emerging treatment options in the newly diagnosed, maintenance, and relapsed/refractory disease settings |
| 5. | Describe education strategies to help patients understand their treatment options | 6. | Develop an evidence-based nursing care plan for patients with multiple myeloma based on disease- and treatment-related symptoms |
| 7. | Describe effective nursing management of common adverse events, including skeletal-related events, peripheral neuropathy, and deep venous thrombosis | 8. | Identify how to help patients cope with long-term survivorship issues |
| 9. | Develop education strategies to help patients understand how to recognize and manage side effects |
| 1. | Explain the pathophysiology of multiple myeloma |
| 2. | Assess the diagnostic workup of patients with multiple myeloma |
| 3. | Describe the various methods of staging multiple myeloma |
| 4. | Assess the latest data on the safety and efficacy of current and emerging treatment options in the newly diagnosed, maintenance, and relapsed/refractory disease settings |
| 5. | Describe education strategies to help patients understand their treatment options |
| 6. | Develop an evidence-based nursing care plan for patients with multiple myeloma based on disease- and treatment-related symptoms |
| 7. | Describe effective nursing management of common adverse events, including skeletal-related events, peripheral neuropathy, and deep venous thrombosis |
| 8. | Identify how to help patients cope with long-term survivorship issues |
| 9. | Develop education strategies to help patients understand how to recognize and manage side effects |
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
| Name of Faculty or Presenter | Reported Financial Relationship |
| Beth Faiman, PhD, MSN, APRN-BC, AOCN® | Consultant/Independent contractor: Celgene Corporation; Millennium Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.; Speakers' bureau: Celgene Corporation; Millennium Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc. |
| Sandra E. Kurtin, MS, RN, ANP-C, AOCN® | Consultant/Independent contractor: Bristol-Myers Squibb Company; Celgene Corporation; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Honoraria: Bristol-Myers Squibb Company; Celgene Corporation; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited. |
| Nikki Barkett, BSN, RN, OCN® | Has no real or apparent conflicts of interest to report. |
| Charise Gleason, MSN, NP-BC, AOCNP® | Has no real or apparent conflicts of interest to report. |
| Amy Pierre, MSN, RN, APN-BC | Speakers' bureau: Amgen, Inc.; Onyx Pharmaceuticals, Inc. |
| Tiffany Richards, RN, MSN, ANP, AOCNP® | Consultant/Independent contractor: Celgene Corporation; Onyx Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited. |
| Kristyn Romanowski, BSN, RN | Speakers' bureau: Celgene Corporation. |
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
| Name of Planner or Manager | Reported Financial Relationship |
|---|---|
| Laura Gilsdorf | Nothing to disclose |
| Andrea Funk | Nothing to disclose |
| Ashley Marostica, RN, MSN | Nothing to disclose |
| Linda Gracie-King, MS | Nothing to disclose |
| Ronald Viggiani, MD | Nothing to disclose |
| Isabelle Vacher | Nothing to disclose |
| Jocelyn Timko, BS | Nothing to disclose |
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AXIS Medical Education do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
There is no fee for this educational activity.
This activity is supported by educational grants provided by Celgene Corporation, Novartis Pharmaceuticals, and Takeda Oncology.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above |
© 2007-2025 HealthCourse, Inc. All rights reserved.
